Published in Drug Discov Today on February 07, 2007
Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl Recept Signal (2008) 1.47
Pharmacology of anabolic steroids. Br J Pharmacol (2008) 1.26
Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands. Chem Biol (2009) 1.14
Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal (2008) 1.11
Sex hormones, aging, and Alzheimer's disease. Front Biosci (Elite Ed) (2012) 1.06
Androgens promote prostate cancer cell growth through induction of autophagy. Mol Endocrinol (2012) 0.95
Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription. ACS Chem Biol (2009) 0.92
Neuronal androgen receptor regulates insulin sensitivity via suppression of hypothalamic NF-κB-mediated PTP1B expression. Diabetes (2012) 0.92
Activity of antiandrogens against juvenile and adult Schistosoma mansoni in mice. J Antimicrob Chemother (2010) 0.90
Tissue selectivity of the anabolic steroid, 19-nor-4-androstenediol-3beta,17beta-diol in male Sprague Dawley rats: selective stimulation of muscle mass and bone mineral density relative to prostate mass. Endocrinology (2007) 0.88
One size may not fit all: anti-aging therapies and sarcopenia. Aging (Albany NY) (2011) 0.85
Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease. ACS Chem Neurosci (2013) 0.82
Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J Biol Chem (2009) 0.82
Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities. J Steroid Biochem Mol Biol (2009) 0.82
Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes (2014) 0.81
Identification of black market products and potential doping agents in Germany 2010-2013. Eur J Clin Pharmacol (2014) 0.79
High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions. Assay Drug Dev Technol (2014) 0.77
Optimizing Ligand Efficiency of Selective Androgen Receptor Modulators (SARMs). ACS Med Chem Lett (2015) 0.75
Modulatory effect of gonadotropins on rats' ovaries after nandrolone decanoate administration: a stereological study. Iran J Med Sci (2014) 0.75
Nonsteroidal androgen receptor ligands: versatile syntheses and biological data. ACS Med Chem Lett (2012) 0.75
Advantages and Limitations of Androgen Receptor-Based Methods for Detecting Anabolic Androgenic Steroid Abuse as Performance Enhancing Drugs. PLoS One (2016) 0.75
Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen. Assay Drug Dev Technol (2016) 0.75
Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev (1997) 6.71
Formation of the androgen receptor transcription complex. Mol Cell (2002) 4.93
Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell (2001) 4.78
ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett (1996) 4.77
Androgen receptor (AR) coregulators: an overview. Endocr Rev (2002) 4.01
Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science (2002) 3.46
Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J (2000) 2.96
Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest (2000) 2.94
Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A (2005) 2.89
Biological actions of androgens. Endocr Rev (1987) 2.81
Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem (2000) 2.60
Androgens and coronary artery disease. Endocr Rev (2003) 2.26
Discovery of nonsteroidal androgens. Biochem Biophys Res Commun (1998) 2.21
The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem (2004) 2.15
Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov (2004) 2.05
Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res (2004) 1.75
Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther (2003) 1.73
Chemistry and structural biology of androgen receptor. Chem Rev (2005) 1.72
Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci U S A (2003) 1.72
Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem Res Toxicol (2003) 1.61
Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab (1999) 1.47
Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology (1999) 1.38
Molecular genetics of steroid 5 alpha-reductase 2 deficiency. J Clin Invest (1992) 1.36
Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab (1999) 1.35
Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J Biol Chem (2005) 1.32
Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet (2004) 1.30
The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton. FASEB J (2002) 1.30
Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology (2005) 1.27
A selective androgen receptor modulator for hormonal male contraception. J Pharmacol Exp Ther (2004) 1.25
Testosterone stimulates intracellular calcium release and mitogen-activated protein kinases via a G protein-coupled receptor in skeletal muscle cells. Endocrinology (2003) 1.15
Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Mol Endocrinol (2005) 1.14
Interplay between two hormone-independent activation domains in the androgen receptor. Cancer Res (2006) 1.10
The androgen receptor: a mediator of diverse responses. Front Biosci (1996) 1.09
New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. Bioorg Med Chem Lett (1998) 1.08
Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol Pharm Bull (2003) 1.05
Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis (2003) 1.05
Selective modulation of genomic and nongenomic androgen responses by androgen receptor ligands. Mol Endocrinol (2003) 1.04
An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology (2006) 1.02
The molecular genetics of steroid 5 alpha-reductases. Recent Prog Horm Res (1994) 1.02
Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. J Steroid Biochem Mol Biol (1993) 1.00
The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology (1996) 1.00
Non-steroidal steroid receptor modulators. Curr Med Chem (2005) 0.98
Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential. Curr Top Med Chem (2006) 0.97
Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. Cancer Res (2003) 0.97
Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm Res (2006) 0.97
Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci U S A (2002) 0.95
Discovery and therapeutic promise of selective androgen receptor modulators. Mol Interv (2005) 0.95
Oestrogen at the neonatal stage is critical for the reproductive ability of male mice as revealed by supplementation with 17beta-oestradiol to aromatase gene (Cyp19) knockout mice. J Endocrinol (2001) 0.92
Testosterone and atherosclerosis. Growth Horm IGF Res (2003) 0.91
The importance of oestrogens in males. Clin Endocrinol (Oxf) (2003) 0.91
Signaling cross-talk from Gbeta4 subunit to Elk-1 in the rapid action of androgens. J Biol Chem (2003) 0.90
Men, bone and estrogen: unresolved issues. Osteoporos Int (2003) 0.89
Estrogen receptor-dependent activation of AP-1 via non-genomic signalling. Nucl Recept (2004) 0.87
Is there a role for estrogens in the maintenance of men's health? Aging Male (2002) 0.84
Medical management of benign prostatic hyperplasia. Geriatr Nephrol Urol (1999) 0.82
Synthesis and biological evaluation of a nonsteroidal bromine-76-labeled androgen receptor ligand 3-[76Br]bromo-hydroxyflutamide. Nucl Med Biol (2006) 0.82
A comparative study of the selectivity and efficiency of target tissue uptake of five tritium-labeled androgens in the rat. J Steroid Biochem (1990) 0.81
Testosterone metabolism, dose-response relationships and receptor polymorphisms: selected pharmacological/toxicological considerations on benefits versus risks of testosterone therapy in men. Aging Male (2003) 0.79
Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin Investig Drugs (2006) 0.78
A comparative molecular modeling study of dydrogesterone with other progestational agents through theoretical calculations and nuclear magnetic resonance spectroscopy. J Steroid Biochem Mol Biol (2005) 0.76
Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A (2005) 2.89
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood (2008) 2.22
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol (2013) 1.78
Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther (2003) 1.73
Chemistry and structural biology of androgen receptor. Chem Rev (2005) 1.72
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2007) 1.69
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol (2003) 1.65
Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J Med Chem (2004) 1.64
Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab (2006) 1.63
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma (2009) 1.58
Synthesis and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides for prostate cancer. Bioorg Med Chem Lett (2004) 1.57
Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med (2011) 1.57
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem (2005) 1.54
Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. J Pharmacol Exp Ther (2003) 1.41
Nonsteroidal selective androgen receptor modulators enhance female sexual motivation. J Pharmacol Exp Ther (2010) 1.39
Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem (2002) 1.39
A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. J Med Chem (2004) 1.35
Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology (2005) 1.27
Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. J Med Chem (2009) 1.27
A selective androgen receptor modulator for hormonal male contraception. J Pharmacol Exp Ther (2004) 1.25
Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. J Med Chem (2010) 1.21
FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res (2010) 1.21
Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem (2009) 1.20
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.12
Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal (2008) 1.11
The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther (2005) 1.10
Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents. J Med Chem (2011) 1.09
Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability. Drug Metab Dispos (2011) 1.04
TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol (2013) 1.03
Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clin Cancer Res (2013) 1.03
Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis. Pharm Res (2012) 1.02
Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents. J Med Chem (2012) 1.02
Estrogen receptor-{beta}-selective ligands alleviate high-fat diet- and ovariectomy-induced obesity in mice. J Biol Chem (2010) 1.01
Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents. Bioorg Med Chem (2009) 1.01
MicroRNAs are mediators of androgen action in prostate and muscle. PLoS One (2010) 1.01
Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res (2003) 1.00
Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol (2008) 1.00
Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa as a negative regulator of androgen receptor (AR) transcriptional activation. J Biol Chem (2004) 0.99
Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization. Bioorg Med Chem (2011) 0.99
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One (2010) 0.99
Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Mol Biol Cell (2013) 0.99
Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol (2007) 0.98
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma. Ther Drug Monit (2008) 0.98
Structure-activity relationship studies of arylthiazolidine amides as selective cytotoxic agents for melanoma. Anticancer Res (2007) 0.97
Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res (2006) 0.97
In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring. Endocrinology (2005) 0.97
Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm Res (2006) 0.97
Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem (2007) 0.96
Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. Bioorg Med Chem Lett (2007) 0.96
Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma. Bioorg Med Chem Lett (2008) 0.95
Discovery and therapeutic promise of selective androgen receptor modulators. Mol Interv (2005) 0.95
Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs (2006) 0.95
Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitor. Cancer Res (2010) 0.94
Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology (2008) 0.93
Drug metabolism and pharmacokinetics of 4-substituted methoxybenzoyl-aryl-thiazoles. Drug Metab Dispos (2010) 0.92
Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy. Endocrinology (2010) 0.91
Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides. Bioorg Med Chem (2006) 0.91
Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs (2010) 0.91
Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry. Anal Chem (2004) 0.90
Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase? Mol Interv (2007) 0.89
17-β estradiol protects ARPE-19 cells from oxidative stress through estrogen receptor-β. Invest Ophthalmol Vis Sci (2010) 0.89
Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties. J Med Chem (2013) 0.87
Discovery of 2-arylthiazolidine-4-carboxylic acid amides as a new class of cytotoxic agents for prostate cancer. J Med Chem (2005) 0.87
Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer. Cancer Res (2010) 0.85
A novel rhodamine-riboflavin conjugate probe exhibits distinct fluorescence resonance energy transfer that enables riboflavin trafficking and subcellular localization studies. Mol Pharm (2005) 0.85
Pre-systemic metabolism prevents in vivo antikinetoplastid activity of N1,N4-substituted 3,5-dinitro sulfanilamide, GB-II-150. Life Sci (2006) 0.85
Synthesis of irreversibly binding bicalutamide analogs for imaging studies. Tetrahedron Lett (2005) 0.85
Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators. Bioorg Med Chem Lett (2008) 0.85
Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen. Int J Cancer (2012) 0.84
A novel liposomal formulation of flavopiridol. Int J Pharm (2008) 0.84
A bifunctional colchicinoid that binds to the androgen receptor. Mol Cancer Ther (2007) 0.83
SAR studies of 2-arylthiazolidine-4-carboxylic acid amides: a novel class of cytotoxic agents for prostate cancer. Bioorg Med Chem Lett (2005) 0.83
Cancer cachexia therapy: a key weapon in the fight against cancer. Curr Opin Clin Nutr Metab Care (2011) 0.83
Domain structure and DNA binding regions of beta protein from bacteriophage lambda. J Biol Chem (2006) 0.83
2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways. Int J Oncol (2010) 0.83
Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin. J Mass Spectrom (2010) 0.83
ERβ selective agonist inhibits angiotensin-induced cardiovascular pathology in female mice. Endocrinology (2013) 0.82
Design, synthesis, and biological evaluation of stable colchicine binding site tubulin inhibitors as potential anticancer agents. J Med Chem (2014) 0.82
Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines. Int J Oncol (2006) 0.81
Estrogen receptor beta selective nonsteroidal estrogens: seeking clinical indications. Expert Opin Ther Pat (2010) 0.81
Characterization of the in vitro metabolism of selective androgen receptor modulator using human, rat, and dog liver enzyme preparations. Drug Metab Dispos (2005) 0.81
Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets. J Med Chem (2011) 0.80
Interspecies differences in pharmacokinetics and metabolism of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)-propionamide: the role of N-acetyltransferase. Drug Metab Dispos (2005) 0.80
Effects of selective androgen receptor modulator (SARM) treatment in osteopenic female rats. Pharm Res (2009) 0.80
Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer. Pharm Res (2012) 0.80
I-387, a novel antimitotic indole, displays a potent in vitro and in vivo antitumor activity with less neurotoxicity. Mol Cancer Ther (2010) 0.79
Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer. Bioorg Med Chem (2006) 0.79
Role of nuclear receptors in lipid dysfunction and obesity-related diseases. Drug Metab Dispos (2012) 0.79
A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer. Cancer Chemother Pharmacol (2010) 0.79
Alanine aminotransferase regulation by androgens in non-hepatic tissues. Pharm Res (2011) 0.79
Synthesis and biological evaluation of novel cytotoxic phospholipids for prostate cancer. Bioorg Med Chem Lett (2004) 0.78
Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin Investig Drugs (2006) 0.78
Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice. Drug Metab Dispos (2011) 0.77
Structure determination of chiral sulfoxide in diastereomeric bicalutamide derivatives. Chirality (2009) 0.77
Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer. J Pharmacol Exp Ther (2006) 0.77
Androgen receptor antagonists: a patent review (2008-2011). Expert Opin Ther Pat (2012) 0.77
Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. Clin Pharmacokinet (2013) 0.77
GTx-822, an ER{beta}-selective agonist, protects retinal pigment epithelium (ARPE-19) from oxidative stress by activating MAPK and PI3-K pathways. Invest Ophthalmol Vis Sci (2010) 0.77